<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        36-42-92
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1992
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HUMULIN 70-30 100U-ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN ISOPHANE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        53.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ELI LILLY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ELI LILLY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AD01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Humulin 70/30 contains the active substance human insulin, which is used to treat diabetes. You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood (blood sugar). Humulin 70/30 is used to control glucose in the long term. It is a premixed suspension of rapid and long acting insulin. Its action is prolonged by the inclusion of protamine sulfate in the suspension.<br />Your doctor may tell you to use Humulin 70/30 as well as a longer-acting insulin. Each kind of insulin comes with its own patient information leaflet to tell you about it. Do not change your insulin unless your doctor tells you to. Be very careful if you do change insulin. Each type of insulin has a different colour and symbol on the pack and the vial so that you can easily tell the difference.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Humulin 70/30 if you:<br />- If you think hypoglycaemia (low blood sugar) is starting</strong>. Further in this leaflet it tells you how to deal with mild hypoglycaemia (see A in Section 4).<br />- If you are allergic to human insulin or any of the other ingredients of this medicine <em>(listed on Section 6)</em>.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor, pharmacist, or nurse before using Humulin <strong>70/30</strong>.</p><ul><li>If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low. Warning signs are listed later in this leaflet. You must think carefully about when to have your meals, how often to exercise and how much to do. You must also keep a close watch on your blood sugar levels by testing your blood glucose often.</li><li>A few people who have had hypoglycaemia (low blood sugar) after switching from animal insulin to human insulin have reported that the early warning symptoms were less obvious or different. If you often have hypoglycaemia or have difficulty recognising the symptoms, please discuss this with your doctor.</li><li>If you answer YES to any of the following questions, tell your diabetes specialist nurse, doctor or pharmacist.</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - Have you recently become ill?<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - Do you have trouble with your kidneys or liver?<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - Are you exercising more than usual?</p><ul><li>The amount of insulin you need may also change if you drink alcohol.</li><li>You should also tell your diabetes specialist nurse, doctor or pharmacist if you are planning to go abroad. The time difference between countries may mean that you have to have your injections and meals at different times to when you are at home.</li><li>Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible, if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</li><li>Perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.</li></ul><p><strong>Other medicines and Humulin 70/30</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Your insulin needs may change if you are taking any of the following:<br />&bull; steroids,<br />&bull; thyroid hormone replacement therapy,<br />&bull; oral hypoglycaemics (antidiabetic medication),<br />&bull; acetylsalicylic acid (aspirin),<br />&bull; growth hormone,<br />&bull; octreotide, lanreotide,<br />&bull; beta2 stimulants (for example ritodrine, salbutamol or terbutaline),<br />&bull; beta-blockers,<br />&bull; thiazides or some antidepressants (monoamine oxidase inhibitors),<br />&bull; danazol,<br />&bull; some angiotensin converting (ACE) inhibitors (for example captopril,enalapril) or angiotensin II receptor blockers.<br /><strong>Pregnancy, breast-feeding and fertility</strong><br />The amount of insulin you need usually falls during the first three months of pregnancy and increases for the remaining six months. If you are breast-feeding, you may need to alter your insulin intake or diet.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>HUMULIN&nbsp;70/30 may pass into your breast milk. Talk with your healthcare provider about the best way to feed your baby while using HUMULIN&nbsp;70/30.<br /><strong>Driving and using machines</strong><br />Your ability to concentrate and react may be reduced if you have hypoglycaemia (low blood sugar). Please remember this in all situations where you might put yourself and others at risk (e.g. driving a car or operating machinery). You should contact your diabetes specialist nurse or doctor about the advisability of driving if you have:<br />&bull; frequent episodes of hypoglycaemia<br />&bull; reduced or absent warning signs of hypoglycaemia.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always check the pack and the vial label for the name and type of the insulin when you get it from your pharmacy. Make sure you get the Humulin that your doctor has told you to use.</strong><br />Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>Dosage</strong></p><ul><li>Your doctor has told you which insulin to use, how much, when and how often to inject. These instructions are only for you. Follow them exactly and visit your diabetes clinic regularly.</li><li>If you change your insulin type (for example from animal to human), you may have to take more or less than before. This might just be for the first injection or it may be a gradual change over several weeks or months.&nbsp;During insulin regimen&rsquo;s changes, your doctor may increase the frequency of glucose monitoring.</li><li>Inject Humulin 70/30 under the skin. You should not administer it using a different administration route. Under no circumstances should Humulin 70/30 be given into a vein.</li><li>Use HUMULIN&nbsp;70/30 exactly as your healthcare provider tells you to. HUMULIN 70/30 is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. Change (rotate) your injection sites within the area you choose with each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. <strong>Do not</strong> use the exact same spot for each injection. <strong>Do not</strong> inject where the skin has pits, is thickened, or has lumps. <strong>Do not</strong> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</li></ul><p><strong>Preparing Humulin 70/30</strong></p><ul><li>Vials containing Humulin 70/30 should be rotated several times in the palms of the hands before use to resuspend insulin until it appears uniformly cloudy or milky. If not, repeat the above procedure until contents are mixed. Do not shake vigorously as this may cause frothing which may interfere with the correct measurement of the dose. The vials should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or sides of the vial, giving it a frosted appearance. Check each time you inject yourself.</li></ul><p><strong>Injecting Humulin 70/30</strong></p><ul><li>First wash your hands.</li><li>Before you make an injection, clean your skin as you have been instructed. Clean the rubber stopper on the vial, but do not remove the stopper.</li><li>Use a clean, sterile syringe and needle to pierce the rubber stopper and draw in the amount of Humulin 70/30 you want. Your doctor or clinic will tell you how to do this.<strong> Do not share your needles and syringes.</strong></li><li>Inject under the skin, as you were taught. Do not inject directly into a vein. After your injection, leave the needle in the skin for 5 seconds to make sure you have taken the whole dose. Do not rub the area you have just injected. Make sure you inject at least half an inch (1 cm) from where you last injected and that you &lsquo;rotate&rsquo; the places you inject, as you have been taught.</li></ul><p><strong>If you take more Humulin 70/30 than you should</strong><br />If you take more Humulin <strong>70/30</strong> than you should, your blood sugar may become low. Check your blood sugar (see A in Section 4).<br /><strong>If you forget to use Humulin 70/30</strong><br />If you use less Humulin 70/30 than you should, your blood sugar levels may increase.</p><p>Check your blood sugar. Do not inject a double dose to make up for a forgotten dose.<br /><strong>If you stop using Humulin 70/30</strong><br />If you use less Humulin 70/30 than you should, your blood sugar levels may become too high. Do not change your insulin unless your doctor tells you to.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Human insulin may cause hypoglycaemia (low blood sugar). See more information on hypoglycaemia below in the subsection &ldquo;Common problems of diabetes&rdquo;.<br />Possible side effects</strong></p><p><strong>Systemic allergy</strong> is very rare (affects less than 1 person in 10, 000). The symptoms are as follows:<br />&bull; fall in blood pressure&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; rash over the whole body<br />&bull; difficulty in breathing&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; wheezing<br />&bull; fast heart beat&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; sweating<br />If you think you are having this sort of insulin allergy with Humulin 70/30, tell your doctor at once.<br /><strong>Local allergy</strong> is common (affects less than 1 person in 10). Some people get redness, swelling or itching around the area of the insulin injection. This usually clears up in anything from a few days to a few weeks. If this happens to you, tell your doctor.<br /><strong>Lipodystrophy </strong>(thickening or pitting of the skin) is uncommon (affects less than 1 person in 100). If you notice your skin thickening or pitting at the injection site, change your injection site and tell your doctor.<br />Oedema (e.g. swelling in arms, ankles; fluid retention) has been reported, particularly at the start of insulin therapy or during a change in therapy to improve control of your blood glucose.<br />Cutaneous amyloidosis: Frequency &#39;not known&#39;</p><p>Lipodystrophy and localized Cutaneous Amyloidosis</p><p>Lipodystrophy and localized cutaneous amyloidosis at the injection site have occurred. Hyperglycemia has been reported with repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions.</p><p><strong>Common problems of diabetes<br />A. Hypoglycaemia</strong><br />Hypoglycaemia (low blood sugar) means there is not enough sugar in the blood. This can be caused if you:<br />&bull; take too much Humulin 70/30 or other insulin;<br />&bull; miss or delay meals or change your diet;<br />&bull; exercise or work too hard just before or after a meal;<br />&bull; have an infection or illness (especially diarrhoea or vomiting);<br />&bull; have a change in your need for insulin; or<br />&bull; have trouble with your kidneys or liver which gets worse.<br />Alcohol and some medicines can affect your blood sugar levels.<br />The first symptoms of low blood sugar usually come on quickly and include the following:<br />&bull; tiredness&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &bull; rapid heartbeat<br />&bull; nervousness or shakiness&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; feeling sick<br />&bull; headache&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &bull; cold sweat<br />Until you become confident in recognising your warning symptoms, avoid situations such as driving a car, in which you or others would be put at risk by hypoglycaemia.</p><p><br /><strong>Do not use Humulin 70/30 if you think hypoglycaemia (low blood sugar) is starting.</strong><br />If your blood sugar is low, eat glucose tablets, sugar or drink a sugary drink. Then eat fruit, biscuits, or a sandwich, as your doctor has advised you and have some rest. This will often get you over mild hypoglycaemia or a minor insulin overdose. If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once. A glucagon injection can treat quite severe hypoglycaemia. Eat glucose or sugar after the glucagon injection. If you do not respond to glucagon, you will have to go to hospital. Ask your doctor to tell you about glucagon.</p><p><br /><strong>B. Hyperglycaemia and diabetic ketoacidosis</strong><br />Hyperglycaemia (too much sugar in the blood) means that your body does not have enough insulin. Hyperglycaemia can be brought about by:<br />&bull; not taking your Humulin 70/30 or other insulin;<br />&bull; taking less insulin than your doctor tells you to;<br />&bull; eating a lot more than your diet allows; or<br />&bull; fever, infection or emotional stress.<br />Hyperglycaemia can lead to diabetic ketoacidosis. The first symptoms come on slowly over many hours or days. The symptoms include the following:<br />&bull; feeling sleepy&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; no appetite<br />&bull; flushed face&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; fruity smell on the breath<br />&bull; thirst&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; feeling or being sick<br />Severe symptoms are heavy breathing and a rapid pulse<strong>. Get medical help immediately.</strong><br />If hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) are not treated they can be very serious and cause headaches, nausea, vomiting, dehydration, unconsciousness, coma or even death.<br /><em><strong>Three simple steps </strong>to avoid hypoglycaemia or hyperglycaemia are:</em><br />&bull; Always keep spare syringes and a spare vial of Humulin <strong>70/30</strong>.<br />&bull; Always carry something to show you are diabetic.<br />&bull; Always carry sugar with you.</p><p><br /><strong>C. Illness</strong><br />If you are ill, especially if you feel sick or are sick, the amount of insulin you need may change.<strong> Even when you are not eating normally, you still need insulin.</strong> Test your urine or blood, follow your &lsquo;sick rules&rsquo;, and tell your diabetes specialist nurse or doctor.<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Before the first use store your Humulin 70/30 in a refrigerator (2&deg;C &ndash; 8&deg;C). <strong>Do not freeze</strong>. You can keep your &lsquo;in use&rsquo; vial at room temperature (below 30&deg;C) for up to 28 days. Do not put it near heat or in the sun.<br />Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month.<br />Do not use this medicine, if you notice that clumps of material are present or solid white particles stick to the bottom or sides of the vial, giving it a frosted appearance. Check this each time you inject yourself.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The <strong>active substance </strong>is human insulin. Human insulin is made in the laboratory by a &lsquo;recombinant DNA technology&rsquo; process. It has the same structure as the natural hormone made by the pancreas. It is therefore different from animal insulins. Humulin 70/30 is a premixed suspension which contains 30 % insulin dissolved in water and 70% insulin with protamine sulfate.<br />- The <strong>other ingredients </strong>are protamine sulfate, metacresol, phenol, glycerol, dibasic sodium phosphate 7H2O, zinc oxide and water for injection. Sodium hydroxide or hydrochloric acid may have been used during manufacture to adjust the acidity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Humulin 70/30 100 IU/ml suspension for injection is a white and cloudy, sterile suspension and contains 100 units of insulin in each millilitre (100 IU/ml). Each vial contains 1000 units (10 millilitres).
Humulin 70/30 100 IU/ml comes in a pack of 1 vial or 2 vials or in multi-packs of 5 (5 x 1) vials.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing authorization holder: Eli Lilly and Company, Indianapolis, IN 46285, USA</p><p>Manufacturer:</p><p>Humulin <strong>70/30 </strong>in vial is made by:</p><p>Eli Lilly and Company, Indianapolis, IN 46285, USA</p><p>For any information about this medicine, please contact the local Marketing Authorisation Holder representative:</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي هيومالين 70/30 على الإنسولين البشري كمادة فعالة، والتي تستخدم في علاج مرض السكري. وعادة ما يوصف المرء بأنه مصاب بداء السكري إذا لم تعد لدى البنكرياس القدرة على إفراز ما يكفي من الإنسولين لضبط مستوى السكر في الدم (سكر الدم). ويستخدم هيومالين 70/30 للتحكم في مستوى السكر على المدى الطويل. وهو عبارة عن مستعلق مسبق المزج من الإنسولين سريع وطويل المفعول. ويتم إطالة أمد مفعوله من خلال تضمين سلفات بروتامين في المستعلق.</p><p dir="RTL">قد ينصحك الطبيب باستخدام هيومالين 70/30 بالإضافة إلى أحد أنواع الإنسولين الأخرى ذات المفعول الأطول. ويُقدم كل نوع من الإنسولين مع نشرة معلومات المريض الخاصة به للإطلاع على كل ما يتعلق بالدواء. ويجب عليك أن لا تُقدم على تغيير نوع الإنسولين إلا إذا نصحك الطبيب بذلك. ولتكن على حذر بالغ عندما تغير نوع الإنسولين. إن لكل نوع من الإنسولين لونه ورمزه المميز على العبوة، وذلك حتى يتسنى لك التمييز بينها بسهولة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم هيومالين 70/30 في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا شعرت ببدء حدوث نقص سكر الدم (انخفاض نسبة السكر في الدم</strong><em>)</em>. ستجد لاحقا في هذه النشرة معلومات لإطلاعك على كيفية التعامل مع النقص الطفيف في سكر الدم (راجع الفقرة أ في القسم 4).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالحساسية للإنسولين البشري أو لأي من المكونات الأخرى الموجودة في هذا الدواء (راجع القسم 6).</p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong></p><p dir="RTL">تحدّث إلى طبيبك أو الصيدلي أو الممرض قبل استخدام هيومالين 70/30.</p><ul dir="rtl"><li>&nbsp;إذا تم التحكم بمستويات السكر في الدم لديك بشكل جيد بواسطة علاج الإنسولين الحالي الذي تتناوله، فقد لا تشعر بالأعراض التحذيرية عندما تنخفض نسبة السكر في الدم لديك إلى مستوى متدنٍ جدًا. وسوف يتم سرد تلك العلامات التحذيرية لاحقاً في هذه النشرة. ويجب عليك أن تأخذ بعين الإعتبار مراعاة الأوقات التي تتناول فيها وجباتك، وعدد المرات التي تمارس فيها تمارينك الرياضية ومقدار تلك التمارين. كما يتعين عليك أيضا أن تبقى مراقبا عن كثب لمستويات السكر في الدم لديك من خلال القيام بعمل اختبار نسبة الجلوكوز في الدم بصفة مستمرة.</li><li>أفاد عدد قليل من الأفراد الذين يعانون من نقص سكر الدم (انخفاض نسبة السكر في الدم) بعد التحول من استخدام الإنسولين الحيواني إلى الإنسولين البشري أن أعراض الإنذار المبكر كانت أقل وضوحا أو مختلفة. لذا فإن كنت ممن يعانون من نقص سكر الدم في معظم الأحيان أو تجد صعوبة في التعرف على أعراضه، يرجى مناقشة هذا الأمر مع طبيبك.</li><li>إذا كانت إجابتك بـ &quot;نعم&quot; على أي من الأسئلة التالية، فعليك أن تخبر ممرضك المتخصص في مرض السكري أو الطبيب أو الصيدلي.</li></ul><p dir="RTL" style="text-indent:50px">- هل أصبحت تشعر أنك مريض مؤخرا؟</p><p dir="RTL" style="text-indent:50px">- هل تعاني من مشاكل في الكليتين أو الكبد؟</p><p dir="RTL" style="text-indent:50px">- هل تمارس تمارين أكثر من المعتاد؟</p><ul dir="rtl"><li>قد يتغير مقدار الإنسولين الذي تحتاج إليه أيضا إذا كنت تتناول الكحوليات.</li><li>يجب أن تخبر ممرضك المتخصص في مرض السكري أو الطبيب أو الصيدلي إذا كانت لديك خطط للسفر إلى الخارج. إذ إن فوارق التوقيت بين البلدان يعني أنك قد تضطر إلى أن يتم حقنك أو أن تتناول وجباتك في أوقات غير تلك التي كان مقررا أن تؤدي فيها ذلك في بلدك.&nbsp; &nbsp;</li><li>بعض المرضى الذين يعانون من مرض السكري نوع 2 لأمد طويل إضافة إلى أمراض القلب، أو الذين أصيبوا مسبقا بالسكتة الدماغية وعولجوا ببيوجليتازون مع الإنسولين، تعرضوا للإصابة بقصور القلب. عليك إبلاغ الطبيب في أقرب وقت ممكن، إذا أصبت بعلامات فشل القلب مثل ضيق تنفس غير عادي أو إذا حدث لديك زيادة سريعة في الوزن أو تورم موضعي (وذمة).</li><li>&nbsp;يجب مناوبة مواقع الحقن باستمرار للحد من خطر الإصابة بالحثل الشحمي (تكتلات تحت الجلد) والداء النشواني الجلدي. هناك خطر محتمل لتأخير امتصاص الإنسولين وتدهور السيطرة على نسبة السكر في الدم بعد حقن الإنسولين في المواقع التي تعاني من هذه التفاعلات (التكتلات الدهنية). أشارت بعض التقارير إلى أن التغير المفاجئ في موقع الحقن إلي منطقة غير متأثرة بالتكتلات الدهنية أدى إلى نقص السكر في الدم. يوصى بمراقبة الجلوكوز في الدم بعد تغيير موقع الحقن، ويمكن النظر في تعديل جرعة الأدوية المضادة لمرض السكري.</li></ul><p dir="RTL"><strong>أدوية أخرى</strong><strong> </strong><strong>وهيومالين 70/30</strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حالياً أو تناولت في الآونة الأخيرة أو تنوي أن تتناول أي أدوية أخرى.</p><p dir="RTL">إن مقدار احتياجك للإنسولين قد يتغير إذا كنت تتناول أيًّا من الأدوية التالية:</p><ul><li dir="RTL">الستيرويدات، &nbsp;</li><li dir="RTL">العلاج البديل لهرمون الغدة الدرقية،</li><li dir="RTL">مخفضات السكري الفموية (الأدوية المضادة لمرض السكر)،</li><li dir="RTL">حمض أسيتيل ساليسيليك (الأسبرين)،</li><li dir="RTL">هرمون النمو،</li><li dir="RTL">أوكتريوتايد، لانريوتايد</li><li dir="RTL">مثيرات بيتا 2 (على سبيل المثال؛ ريتودرين أو سالبوتامول أو تيربوتالين)؛ &nbsp;</li><li dir="RTL">حاصرات بيتا؛ &nbsp;</li><li dir="RTL">أدوية الثيازيد أو بعض مضادات الإكتئاب (مثبطات الإنزيم المؤكسد لأحادي الأمين)؛&nbsp;</li><li dir="RTL">دانازول؛</li><li dir="RTL">بعض مثبطات الإنزيم المحول للأنجيوتنسين (على سبيل المثال؛ كابتوبريل، إنالابريل)؛ أو حاصرات مستقبلات أنجيوتنسين II.</li></ul><p dir="RTL"><strong>الحمل والإرضاع والخصوبة</strong></p><p dir="RTL">عادة ما ينخفض مستوى احتياجك من الإنسولين خلال الأشهر الثلاثة الأولى من الحمل، ويتزايد مقدار احتياجك له خلال الأشهر الستة المتبقية. إذا قمت بعد الوضع بإرضاع طفلك طبيعيا، فقد تحتاجين إلى تغيير جرعتك من الإنسولين أو تغيير نظامك الغذائي.</p><p dir="RTL">إذا كنت حاملاً أو ترضعين رضاعة طبيعية، أو تشكين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي&nbsp;قبل استخدام هذا الدواء.</p><p dir="RTL"><strong>قد ينتقل هومالين 70/30 إلى حليب الثدي. تحدثي مع مقدم الرعاية الصحية الخاص بك حول أفضل طريقة لإطعام طفلك أثناء استخدام هومالين 70/30</strong><strong>.</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">إذا كنت تعاني من نقص سكر الدم (انخفاض نسبة السكر في الدم)، فإن ذلك قد ينشأ عنه انخفاض قدرتك على التركيز والإستجابة. ونرجو أن تنتبه لذلك في جميع المواقف التي يمكن أن تعرض فيها نفسك وآخرين معك للخطر (مثل قيادة السيارة أو تشغيل الآلات). ويتوجب عليك الإتصال بطبيبك أو بممرضتك المتخصصة في السكري للإستشارة بشأن قيادة السيارة إذا كنت تعاني من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات متكررة من نقص سكر الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو انعدام العلامات التحذيرية لنقص سكر الدم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قم دائما بتفحص العبوة وملصق العبوة للتأكد من إسم ونوع الإنسولين عندما تحصل عليه من الصيدلية. وتأكد أن الذي بين يديك هو نفس الهيومالين الذي أوصاك طبيبك باستخدامه.</strong></p><p dir="RTL">التزم دائما باستخدام هذا الدواء تماما كما وصفه لك طبيبك أو الصيدلي. وإذا لم تكن متأكدا بشأن شيء ما، يجب أن تستشير طبيبك أو الصيدلي.</p><p dir="RTL"><strong>الجرعة</strong></p><ul dir="rtl"><li>لقد أخبرك الطبيب بنوع الإنسولين الذي سوف تستخدمه، وبمقدار وعدد المرات التي يتم فيها الحقن. تلك التعليمات موجهة لك وتخصك أنت فقط، ويجب عليك اتباعها حرفيا والتردد على عيادة السكري التي تتابع معها بصفة منتظمة.</li><li>إذا قمت بتغيير نوع الإنسولين (على سبيل المثال من الحيواني إلى البشري)، فقد يصبح من الضروري عليك أن تأخذ جرعة أكثر أو أقل من ذي قبل. ويمكن بدء التغيير من الحقنة الأولى أو ربما يكون تغييرًا تدريجيًا على مدى عدة أسابيع أو أشهر.</li><li>خلال تغييرات نظام الإنسولين، قد يزيد طبيبك من وتيرة (معدل) مراقبة الجلوكوز.</li><li>قم بحقن هيومالين 70/30 تحت الجلد، ويجب أن لا تأخذه بالطرق الأخرى المختلفة لتلقي الدواء. ولا ينبغي تحت أي ظرف من الظروف حقن هيومالين 70/30 في الوريد.</li><li>استخدم هيومالين 70/30 تمامًا كما شرح لك مقدم الرعاية الصحية الخاص بك. يتم حقن هيومالين 70/30 تحت الجلد في منطقة المعدة أو الأرداف أو أعلى الساقين أو الذراعين. قم بتغيير (تدوير) مواقع الحقن داخل المنطقة التي تختارها مع كل جرعة لتقليل خطر الإصابة بالحثل الشحمي (ندبات بالبشرة أو زيادة سماكة الجلد) [MA1]&nbsp;والداء النشواني الجلدي الموضعي (كتل تحت البشرة) في مواقع الحقن. لا تحقن في مواقع الحثل الشحمي (التكتلات الدهنية) والداء النشواني الجلدي الموضعي. <strong>لا</strong> تستخدم نفس الموضع بالضبط لكل حقنة. <strong>لا</strong> تحقن في الجلد حيث توجد حفر، أو سماكة، أو به كتل. <strong>لا</strong> تحقن حيث يكون الجلد طريًا أو فيه كدمات أو متقشر أو صلب أو فيه ندوب أو&nbsp; تلف.</li></ul><p dir="RTL"><strong>تحضير هيومالين 70/30 &nbsp;</strong></p><ul dir="rtl"><li>&nbsp;يجب تدوير العبوة التي تحتوي على الهيومالين 70/30 بين راحتي اليدين عدة مرات قبل الإستخدام مباشرة لإعادة حالة الإستعلاق للإنسولين حتى يبدو متعكرا أو مستحلبا على نحو متجانس. وإذا لم يحدث ذلك، قم بتكرير الإجراء أعلاه حتى تمتزج كافة المحتويات. <strong>ويجب عليك أن لا</strong> ترج بقوة لأن ذلك قد يتسبب في عمل رغوة، الأمر الذي قد ينشأ عنه تضارب في المقياس الصحيح للجرعة. وينبغي فحص العبوة بصفة متكررة، ويجب عدم استخدامها إذا كان بها كتل وتجمعات للمواد أو إذا التصقت الجزيئات الصلبة البيضاء بقاع أو بجدار العبوة، مما يعطيها مظهرا بلوريا. وعليك فحصها في كل مرة تقوم بحقن نفسك.</li></ul><p dir="RTL"><strong>حقن الهيومالين 70/30</strong></p><ul dir="rtl"><li>&nbsp;أولا قم بغسل يديك.</li><li>قبل أن تجري الحقن، قم بتنظيف بشرتك على النحو الذي تم إرشادك إليه. قم بتنظيف السدادة المطاطية على العبوة، ولا تقم بإزالة السدادة.</li><li>استخدم حقنة نظيفة، معقمة وإبرة لثقب السدادة المطاطية وسحب كمية إنسولين هيومالين 70/30 التي تحتاجها. سيخبرك طبيبك أو المختص في العيادة بكيفية القيام بذلك .<strong>لا تشارك أحدا الإبر والحقن الخاصة بك.</strong></li><li>ثم قم بالحقن تحت الجلد بالطريقة التي تعلمتها. <strong>يجب أن</strong> <strong>لا </strong>تحقن مباشرة في الوريد. وبعد الحقن، اترك الإبرة في الجلد لمدة 5 ثوان للتأكد من أنك أخذت الجرعة بالكامل. وينبغي أن لا تفرك المنطقة التي حقنتها للتو. وعليك التحقق من أنك تحقن فيما لا يقل عن نصف بوصة (1 سم) من المكان الذي حقنت فيه آخر مرة، وأنك تعمل على تغيير الأماكن التي تحقن فيها، وذلك بالطريقة التي تعلمتها.</li></ul><p dir="RTL"><strong>إذا أخذت من هيومالين 70/30 أكثر مما يجب</strong></p><p dir="RTL">إذا أخذت من هيومالين 70/30 أكثر مما يجب، فقد تنخفض نسبة السكر في الدم لديك. لذا قم بقياس مستوى السكر في الدم (انظر الفقرة أ من القسم 4).</p><p dir="RTL"><strong>إذا نسيت أن تستخدم هيومالين 70/30 &nbsp;</strong></p><p dir="RTL">إذا أخذت من هيومالين 70/30 مقدارا يقل عن ما يجب، فقد تزداد مستويات السكر في الدم لديك. وعليك قياس مستوى السكر في الدم. لا تحقن جرعة مضاعفة للتعويض عن جرعة منسية.</p><p dir="RTL"><strong>إذا توقفت عن استخدام هيومالين 70/30 </strong></p><p dir="RTL">إذا أخذت هيومالين 70/30 بمقدار أقل مما يجب، فإن مستويات السكر في الدم قد تصبح مرتفعة بشدة. وعليك أن لا تغير نوع الإنسولين الذي تستخدمه إلا إذا نصحك الطبيب بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض</p><p>&nbsp;[MA1]ندبات بالبشرة أو زيادة سماكة الجلد</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأن جميع الأدوية الأخرى، يمكن أن ينشأ عن هيومالين 70/30 بعض الآثار الجانبية، على الرغم من أنه ليس بالضرورة أن يتعرض لها جميع الأفراد.</p><p dir="RTL"><strong>قد يتسبب الإنسولين البشري في نقص سكر الدم (انخفاض نسبة السكر في الدم). ويمكنك الإطلاع على المزيد من المعلومات حول نقص سكر الدم في الفقرة الفرعية التي تأتي بعنوان &quot;المشكلات الشائعة لمرض&nbsp;السكري&quot;.</strong></p><p dir="RTL"><strong>الآثار الجانبية المحتملة</strong></p><p dir="RTL"><strong>الحساسية العامة</strong> نادرة جدًا (تؤثر على أقل من شخص واحد من بين 10،000 شخص). والأعراض هي كما يلي :</p><p dir="RTL">&bull; انخفاض في ضغط الدم&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &bull; طفح جلدي على الجسم كله</p><p dir="RTL">&bull; صعوبة في التنفس &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; أزيز</p><p dir="RTL">&bull; سرعة ضربات القلب&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; التعرق</p><p dir="RTL">إذا كنت تعتقد أن لديك هذا النوع من الحساسية للإنسولين عند استخدام هيومالين 70/30، بادر بإخبار طبيبك على الفور.</p><p dir="RTL"><strong>الحساسية الموضعية</strong> شائعة (تؤثر على أقل من شخص واحد من بين كل 10 أشخاص). حيث قد يصاب بعض الناس باحمرار أو تورم أو حكة في المنطقة المحيطة بمكان حقن الإنسولين. وهذا عادة ما يزول تماما في فترة تتراوح بين بضعة أيام إلى بضعة أسابيع. وإذا حدث ذلك لك، فأخبر به طبيبك.</p><p dir="RTL"><strong>الحثل الشحمي</strong> (زيادة سمك الجلد أو تخدده) غير شائع الحدوث (يؤثر على أقل من شخص واحد من بين 100 شخص). إذا لاحظت زيادة في سمك الجلد أو تخدد في موقع الحقن، قم بتغيير موضع الحقن وأخبر طبيبك بذلك.</p><p dir="RTL">تم تقرير حدوث الأوديما (مثلا، التورم في الذراعين، الكاحلين، احتباس السوائل)، خصوصا عند بداية العلاج بالإنسولين أو أثناء تغيير&nbsp;العلاج لتحسين السيطرة على سكر الدم لديك.</p><p dir="RTL">داء النشواني الجلدي الموضعي: الوتيرة غير معروفة</p><p dir="RTL">الحثل الشحمي (التكتلات الدهنية) والداء النشواني الجلدي الموضعي</p><p dir="RTL">لقد حدث الحثل الشحمي (التكتلات الدهنية) والداء النشواني الجلدي الموضعي في موقع الحقن. تم الإبلاغ عن ارتفاع السكر في الدم مع الحقن المتكرر للإنسولين في مناطق الحثل الشحمي (التكتلات الدهنية) &nbsp;أو الداء النشواني الجلدي الموضعي. وقد تم الإبلاغ عن نقص السكر في الدم مع التغيير المفاجئ في موقع الحقن إلى موضع غير متضرر. يمكن أن تساعد مناوبة أو تدوير مواقع الحقن باستمرار داخل مناطق الحقن المناسبة على تقليل أو منع هذه التفاعلات.</p><p dir="RTL"><strong>المشكلات الشائعة لمرض السكري</strong></p><p dir="RTL"><strong>أ) نقص سكر الدم. </strong></p><p dir="RTL">نقص سكر الدم (انخفاض نسبة السكر في الدم) يعني عدم وجود ما يكفي من السكر في الدم. وهذا من الممكن أن يحدث في الحالات التالية:</p><ul dir="rtl"><li>أخذ مقدار كبير من هيومالين 70/30 أو أيّ من أنواع الإنسولين الأخرى؛</li><li>عدم تناول بعض وجبات الطعام أو تأخير أو تغيير نظامك الغذائي؛</li><li>ممارسة الرياضة أو العمل الشاق قبل أو بعد تناول الوجبة مباشرة؛</li><li>الإصابة بعدوى أو بمرض (خصوصا الإسهال والتقيؤ)؛</li><li>تغير في مقدار حاجتك إلى الإنسولين؛ أو</li><li>إذا كنت تعاني من مشاكل في الكليتين أو الكبد ثم تزداد تلك المعاناة سوءًا.</li></ul><p dir="RTL">يمكن للكحوليات وكذا بعض الأدوية أن تؤثر على مستويات السكر في الدم.</p><p dir="RTL">عادة ما تظهر الأعراض الأولية لانخفاض السكر في الدم سريعا، وتشمل تلك الأعراض ما يلي:</p><p dir="RTL">&bull; التعب &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&bull; سرعة ضربات القلب</p><p dir="RTL">&bull; العصبية أو الإرتعاش&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &bull; الشعور بالإعياء</p><p dir="RTL">&bull; الصداع&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &bull; عرق بارد</p><p dir="RTL">إلى حين أن تصبح على ثقة من قدرتك على تمييز الأعراض التحذيرية، حاول تجنب بعض المواقف مثل قيادة سيارة، حيث في موقف كهذا سوف تكون أنت ومن معك عرضة للخطر بسبب نقص سكر الدم.</p><p dir="RTL"><strong>لا تستخدم هيومالين 70/30 إذا شعرت أنك بدأت تعاني من نقص سكر الدم (انخفاض نسبة السكر في الدم).</strong></p><p dir="RTL">إذا انخفض مستوى السكر في الدم لديك، قم بابتلاع أقراص الجلوكوز، أو تناول السكر أو مشروب سكري. بعد ذلك تناول الفاكهة أو البسكويت أو شطيرة، حسبما نصحك به طبيبك وخذ قسطا من الراحة. وهذا في الغالب يجعلك تتغلب على الانخفاض الطفيف في سكر الدم أو الجرعة الزائدة من الإنسولين بشكل طفيف. إذا ساءت حالتك وأصبح تنفسك أقل عمقاً من التنفس الطبيعي واستحال لون جلدك شاحبا، يجب أن تخبر طبيبك على الفور. ويمكن لحقن الجلوكاجون أن يعالج نقص سكر الدم الحاد تماما. قم بتناول الجلوكوز أو السكر بعد حقن الجلوكاجون. وإذا لم تستجب للجلوكاجون، يصبح لزاما عليك أن تتوجه إلى المستشفى. واطلب من طبيبك أن يخبرك بمعلومات حول الجلوكاجون.</p><p dir="RTL"><strong>ب) فرط سكر الدم والحمض الكيتوني السكري</strong></p><p dir="RTL">فرط سكر الدم (الارتفاع الشديد لمستوى السكر في الدم) يعني أن الجسم لا يوجد به ما يكفي من الإنسولين. ويمكن الإصابة بفرط سكر الدم عن طريق أحد الطرق الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم أخذ هيومالين 70/30 أو أي إنسولين آخر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخذ مقدار من الإنسولين أقل مما وصفه الطبيب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الكثير من الأطعمة أكثر مما يسمح به نظامك الغذائي؛ أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالحمى أو العدوى أو التوتر النفسي.</p><p dir="RTL">ويمكن أن يؤدي فرط سكر الدم إلى الحماض الكيتوني السكري. وتظهر الأعراض الأولى بشكل بطيئ على مدى عدة ساعات أو أيام. وتتضمن تلك الأعراض ما يلي:</p><p dir="RTL">&bull; الشعور بالنعاس&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; فقدان الشهية</p><p dir="RTL">&bull; احمرار الوجه&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&bull; صدور رائحة فواكه عند التنفس</p><p dir="RTL">&bull; العطش&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &bull; الشعور بالغثيان</p><p dir="RTL">وتتمثل الأعراض الحادة في تثاقل التنفس وسرعة النبض. <strong>عليك في هذه الحالة الحصول على المساعدة الطبية فورا.</strong></p><p dir="RTL">إذا لم يتم علاج نقص سكر الدم (انخفاض نسبة السكر في الدم) أو فرط سكر الدم (الإرتفاع الشديد لمستوى السكر في الدم)، فإنه من الممكن أن يمثلا خطورة شديدة ويتسببا في الصداع والغثيان والتقيؤ والجفاف وفقدان الوعي والغيبوبة أو حتى الموت.</p><p dir="RTL"><em>إليك <strong>ثلاث خطوات بسيطة</strong> لتجنب نقص سكر الدم أو فرط سكر الدم:</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ دائما بمحاقن احتياطية وكذا قارورة احتياطية من هيومالين 70/30.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمل معك دائما ما يفيد بأنك مصاب بالسكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;احمل معك كمية من السكر دائما.</p><p dir="RTL"><strong>ج) المرض</strong></p><p dir="RTL">إذا كنت مريضا، وعلى وجه الخصوص إذا كنت تشعر بالإعياء أو كنت مصاباً بالإعياء بالفعل، فإن مقدار ما تحتاج إليه من الإنسولين قد يتغير. <strong>حتى عندما لا تتناول طعامك بشكل معتاد، فأنت لا تزال بحاجة إلى الإنسولين</strong>. قم بعمل اختبار للبول أو للدم، واتبع &quot;قواعد المرض&quot; الخاصة بك، وأخبر ممرضك المتخصص في السكري أو طبيبك.</p><p dir="RTL"><strong>&nbsp;الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا شعرت بأيّ آثار جانبية، تحدّث مع طبيبك أو الصيدلي أو الممرض. ويشمل هذا أيّ آثار جانبية محتملة غير مدرجة في هذه النشرة. یمکنك أیضا الإبلاغ عن الآثار الجانبیة مباشرة من خلال نظام الإبلاغ الوطني المدرج في القسم 6. من خلال الإبلاغ عن الآثار الجانبیة یمکنك المساعدة في توفیر المزید من المعلومات حول سلامة ھذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدا عن نظر ومتناول الأطفال.</p><p dir="RTL">قبل أول استخدام، احرص على حفظ هيومالين 70/30 &nbsp;في الثلاجة (2&nbsp; &ndash; 8 درجات مئوية) <strong>و</strong>لا <strong>تجمد</strong>ه. واحفظ قارورة هيومالين 70/30 التي هي &quot;قيد الاستعمال&quot; في درجة حرارة الغرفة (أقل من 30 درجة مئوية) لمدة أقصاها 28 يوما. ولا تضعها بمقربة من مصدر للحرارة أو في الشمس.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المنصوص عليه في الملصق والكرتونة. ويشير تاريخ الإنتهاء إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت وجود كتل من المواد أو إذا التصقت جزيئات صلبة بيضاء بقاع أو بجدار القارورة، مما يعطيها مظهراً بلوريًا. وعليك التحقق من ذلك في كل مرة تقوم فيها بحقن نفسك.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق إلقائها في مياه الصرف الصحي أو إلقائها في النفايات المنزلية. وعليك أن تسأل الصيدلي عن كيفية التخلص من الأدوية التي لم يعد ثمة حاجة إليها. فهذه التدابير من شأنها المساعدة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعالة</strong> هي الإنسولين البشري. يتم تحضير الإنسولين البشري في المختبر من خلال عملية &quot;تقنية إعادة دمج الحمض النووي&quot;. فهو له نفس بنية الهرمون الطبيعي الذي يفرزه البنكرياس. ومن ثم فهو مختلف عن الإنسولين الحيواني. ويعد هيومالين 70/30 مستعلق مسبق المزج يحتوي على 30٪ من الإنسولين المذاب في الماء و70٪ من الإنسولين الممزوج مع سلفات البروتامين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> عبارة عن سلفات بروتامين، ميتاكريزول، فينول، جلسرين، فوسفات الصوديوم ثنائي القاعدة 7H2O، أكسيد الزنك وماء للحقن. ويمكن أن يستخدم هيدروكسيد الصوديوم أو حمض الهيدروكلوريك أثناء عملية التصنيع لمعادلة الحمضية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هيومالين 70/30 100 وحدة دولية / مل هو مستعلق للحقن أبيض اللون، غائم، معقم يحتوي على 100 وحدة من الإنسولين في كل مليلتر (100 وحدة دولية / مل). تحتوي كل قارورة على 1000 وحدة (10 مليلتر).</p><p dir="RTL">يوجد هيومالين 70/30 100 وحدة دولية / مل في عبوة قارورة واحدة أو قارورتين أو في حزمة من العبوات تتكون من) 5 5 &times; 1 (قارورات.</p><p dir="RTL">يمكن أن لا تكون جميع أحجام العبوات مسوّقة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">صاحب رخصة التسويق: إيلي ليلي آند كومباني، إنديانابوليس، IN 46285، الولايات المتحدة الأمريكية.&nbsp;</p><p dir="RTL">الشركة المصنعة:&nbsp;</p><p dir="RTL">تم تصنيع قوارير هيومالين 70/30 من قبل:</p><p dir="RTL">إيلي ليلي آند كومباني، إنديانابوليس، IN 46285، الولايات المتحدة الأمريكية. &nbsp;</p><p dir="RTL">للحصول على أية معلومات تتعلق بهذا الدواء، يرجى الإتصال بالمندوب المحلي للشركة التي لها حقوق التسويق:</p><p dir="RTL">شركة إيلي ليلي آند كومباني- المملكة العربية السعودية</p><p dir="RTL">ص.ب92120 :</p><p dir="RTL">الطابق16 ، مبنى رقم 3074</p><p dir="RTL">برج ب، أبراج العُليَّا</p><p dir="RTL">شارع الأمير محمد بن عبد العزيز</p><p dir="RTL">العُليَّا، الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">الخط المباشر: 966114617850+،&nbsp; 966114617800+</p><p dir="RTL">الفاكس:&nbsp; &nbsp;966112179900+</p><p dir="RTL">&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Humulin 70/30 100 IU/ml suspension for injection in vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml contains 100 IU insulin human (produced in E. coli by recombinant DNA technology).
One vial contains 10 ml equivalent to 1000 IU of biphasic isophane insulin –
30 % soluble insulin / 70 % isophane insulin.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A suspension for injection in a vial.
Humulin 70/30 is a sterile suspension of human insulin in the proportion of 30 % soluble insulin to 70% isophane insulin.It is a white and cloudy suspension available as 3 mL multiple-dose vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />The dosage should be determined by the physician, according to the requirement of the patient.&nbsp;During changes to a patient&rsquo;s insulin regimen, increase the frequency of glucose monitoring.<br /><em>Paediatric population</em><br />No data are available<br /><u>Method of administration</u><br />Humulin 70/30 should be given by subcutaneous injection but may, although not recommended, also be given by intramuscular injection. This formulation should not be administered intravenously.<br />Subcutaneous administration should be in the upper arms, thighs, buttocks or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month, in order&nbsp;to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.</p><p>Care should be taken when injecting any Humulin insulin preparations to ensure that a blood vessel has not been entered. After any insulin injection, the injection site should not be massaged. Patients must be educated to use proper injection techniques.<br />Humulin Mixture formulation is a ready-made defined mixture of soluble and isophane insulin designed to avoid the need for the patient to mix insulin preparations. A patient&#39;s treatment regimen should be based on their individual metabolic requirements.<br />Each pack contains a patient information leaflet with instructions on how to inject insulin.</p><p>Administer in the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. During changes to a patient&rsquo;s insulin regimen, increase the frequency of blood glucose monitoring.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypoglycaemia.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, unless used as part of a desensitisation programme.
Under no circumstances should any Humulin formulation other than Humulin S (Soluble) be given intravenously.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (soluble, isophane, mixture), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.<br />Some patients taking human insulin may require a change in dosage from that used with animal-source insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.<br />A few patients who experienced hypoglycaemic reactions after transfer to human insulin have reported that the early warning symptoms were less pronounced or different from those experienced with their previous animal insulin. Patients whose blood glucose is greatly improved, e.g. by intensified insulin therapy, may lose some or all of the warning symptoms of hypoglycaemia and should be advised accordingly. Other conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, diabetic nerve disease, or medications such as beta blockers. Uncorrected hypoglycaemic and hyperglycaemic reactions can cause loss of consciousness, coma or death.</p><p>The use of dosages which are inadequate or discontinuation of treatment, especially in insulin-dependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.<br />Treatment with human insulin may cause formation of antibodies, but titres of antibodies are lower than those to purified animal insulin.<br />Insulin requirements may change significantly in diseases of the adrenal, pituitary or thyroid glands and in the presence of renal or hepatic impairment.<br />Insulin requirements may be increased during illness or emotional disturbances.</p><p>Adjustment of insulin dosage may also be necessary if patients change their level of physical activity or change their usual diet.<br /><u>Combination of human insulin with pioglitazone</u><br />Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind, if treatment with the combination of pioglitazone and human insulin is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued, if any deterioration in cardiac symptoms occurs.</p><p>Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen</p><p>Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia.</p><p>Make any changes to a patient&rsquo;s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.</p><p>Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.</p><p>Excipients<br />This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of medicinal products are known to interact with glucose metabolism and therefore the physician should be consulted when using other medications in addition to human insulin (see section 4.4). The physician must therefore take possible interactions into account and should always ask his patients about any medicinal products they take.<br />Insulin requirements may be increased by substances with hyperglycaemic activity, such as glucocorticoids, thyroid hormones, growth hormone, danazol, beta2- sympatomimetics (such as ritodrine, salbutamol, terbutaline), thiazides.<br />Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics (OHA), salicylates (for example, acetylsalicylic acid), certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme (ACE) inhibitors (captopril, enalapril), angiotensin II receptor blockers, non-selective beta-blocking agents and alcohol.<br />Somatostatin analogues (octreotide, lanreotide) may both decrease or increase insulin dose requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p><u>Risk Summary</u></p><p>Available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations). Animal reproduction studies were not performed.</p><p>The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c &gt;7% and has been reported to be as high as 20-25% in women with a HbA1c &gt;10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p><u>Clinical Considerations</u></p><p><em>Disease-associated maternal and/or embryo/fetal risk</em></p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</p><p>Data</p><p><u>Human Data</u></p><p>While available studies cannot definitively establish the absence of risk, published data from retrospective studies, open-label, randomized, parallel studies and meta-analyses over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. All available studies have methodological limitations, including lack of blinding, unclear methods or randomization, and small sample size.</p><p>It is essential to maintain good control of the insulin treated (insulin-dependent or gestational diabetes) patient throughout pregnancy. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients with diabetes should be advised to inform their doctors if they are pregnant or are contemplating pregnancy.<br />Careful monitoring of glucose control, as well as general health, is essential in pregnant patients with diabetes.</p><p>Lactation</p><p><u>Risk Summary</u></p><p>Available data from published literature suggests that exogenous human insulin products, including HUMULIN&nbsp;70/30, are transferred into human milk. There are no adverse reactions reported in breastfed infants in the literature. There are no data on the effects of exogenous human insulin products, including HUMULIN&nbsp;70/30 on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for HUMULIN&nbsp;70/30 and any potential adverse effects on the breastfed child from HUMULIN&nbsp;70/30 or from the underlying maternal condition.</p><p>Patients with diabetes who are lactating may require adjustments in insulin dose and/or diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).<br />Patients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypoglycaemia is the most frequent undesirable effect of insulin therapy that a patient with diabetes may suffer. Severe hypoglycaemia may lead to loss of consciousness, and in extreme cases, death. No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors e.g. a patient`s level of diet and exercise.<br />Local allergy in patients is common (&ge;1/100 to &lt; 1/10). Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, local reactions may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.<br />Systemic allergy, which is very rare (&lt; 1/10,000) but potentially more serious, is a generalised allergy to insulin. It may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalised allergy may be life-threatening. In the rare event of a severe allergy to Humulin, treatment is required immediately. A change of insulin or desensitisation may be required.<br />Lipodystrophy at the injection site is uncommon (&ge;1/1,000 to &lt; 1/100).<br />Cases of oedema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy.</p><p>Cutaneous amyloidosis: Frequency &lsquo;not known&rsquo;.</p><p><u>Lipodystrophy and localized Cutaneous Amyloidosis</u></p><p>Lipodystrophy and localied cutaneous amyloidosis at the injection site have&nbsp;occurred. Hyperglycemia has been reported with repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.&nbsp;Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (See section 4.4).</p><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed here after.</p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Center (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Insulin has no specific overdose definitions, because serum glucose concentrations are a result of complex interactions between insulin levels, glucose availability and other metabolic processes. Hypoglycaemia may occur as a result of an excess of insulin relative to food intake and energy expenditure.<br />Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.<br />Mild hypoglycaemic episodes will respond to oral administration of glucose or sugar products.<br />Correction of moderately severe hypoglycaemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fail to respond to glucagon must be given glucose solution intravenously.<br />If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously. However, glucose solution must be given intravenously, if glucagon is not available or if the patient fails to respond to glucagon. The patient should be given a meal as soon as consciousness is recovered.<br />Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may occur after apparent clinical recovery.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Insulins and analogues for injection, intermediate acting combined with fast acting.<br />ATC code: A10A D01.<br />Humulin 70/30 is premixed suspension of rapid and intermediate acting insulin.<br />The prime activity of insulin is the regulation of glucose metabolism.<br />In addition insulin has several anabolic and anti-catabolic actions on a variety of different tissues. Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.<br />The typical activity profile (glucose utilisation curve) following subcutaneous injection is illustrated below by the heavy line. Variations that a patient may experience in timing and/or intensity of insulin activity are illustrated by the shaded area. Individual variability will depend on factors such as size of dose, site of injection temperature and physical activity of the patient.</p><p><img alt="" width="1152" height="648" src="data:image/png;base64,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" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of insulin do not reflect the metabolic action of that hormone. Therefore, it is more appropriate to examine glucose utilisation curves (as discussed above) when considering the activity of insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Humulin is human insulin produced by recombinant technology. No serious events have been reported in subchronic toxicology studies. Human insulin was not mutagenic in a series of in vitro and in vivo genetic toxicity assays.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>m-cresol<br />glycerol<br />phenol<br />protamine sulfate<br />dibasic sodium phosphate 7H2O<br />zinc oxide<br />water for injections.<br />The following may be used to adjust pH; hydrochloric acid and/or sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Humulin preparations should not be mixed with insulins produced by other manufacturers or with animal insulin preparations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials
3 years.
After first use
28 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not freeze. Do not expose to excessive heat or direct sunlight.<br /><u><em>Unopened vials</em></u><br />Store in a refrigerator (2&deg;C - 8&deg;C).<br /><u><em>After first use</em></u><br />Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml of suspension in a vial (type I glass) with a stopper (rubber) sealed with a seal (aluminium) combined with a flip top (plastic). Pack size 1 or 2 or (5 x 1). Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not reuse needles. Dispose of the needle in a responsible manner. Needles must not be shared. Vials can be used until empty, then properly discard. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>Dispense in the original sealed carton with the enclosed Instructions for Use.<br /><u>Instructions for use and handling</u><br />A suspension for injection in a 10ml vial to be used in conjunction with an appropriate syringe (100 IU/ml markings).<br />a) Preparing a dose<br />Vials containing Humulin M3 formulation should be rotated several times in the palms of the hands before use to completely resuspend the insulin, until it appears uniformly cloudy or milky. If not, repeat the above procedure until contents are mixed.<br />Do not shake vigorously as this may cause frothing, which may interfere with the correct measurement of the dose.<br />The vials should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the vial, giving a frosted appearance.<br />Prepare your syringe prior to injection, as directed by your doctor or diabetes specialist nurse.<br />Use an insulin syringe marked for the strength of insulin being administered.</p><p>b) Injecting a dose<br />Inject the correct dose of insulin, as directed by your doctor or diabetes specialist nurse.<br />Use of the injection sites should be rotated so that the same is not used more than approximately once a month.<br />Each pack contains a patient information leaflet with instructions on how to inject insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly and Company, Indianapolis, IN 46285, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 June 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>